Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
PhytoSquene now available for clinical and commercial use
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated
